AgomAb Therapeutics NV (AGMB) stock
AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 23, 2026Score 2/30
$5.92−0.05 (-0.84%)
Close on Nov 17, 2026Market cap $148.00KP/E –Yield –
AgomAb Therapeutics gross margin
Gross margin is gross profit as a percentage of revenue.
No gross margin figures for AgomAb Therapeutics
AgomAb Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?